L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Selon Oxfam International...l’industrie pharmaceutique empêche des millions de personnes pauvres d’avoir accès aux médicaments, mettant ainsi en péril son propre devenir...Sanofi-Aventis proposait son médicament ...Plavix à un prix 60 fois supérieur à ...[la] version générique indienne du médicament...Pfizer a ainsi intenté un procès au gouvernement des Philippines pour l’usage de clauses de sauvegarde invoquant la santé publique à l’égard du médicament Norvasc...

Sequenza temporale

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Feb 2008

Content Type:

Company Response

Available languages: English
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

19 Dic 2007

Content Type:

Company Response

Available languages: English
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

18 Dic 2007

Content Type:

Company Response

Available languages: English
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

18 Dic 2007

Content Type:

Company Response

Available languages: English
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Data:

12 Dic 2007

Content Type:

Company Response

Available languages: English
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dic 2007

Content Type:

Company Response

Available languages: English
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dic 2007

Content Type:

Company Response

Available languages: English
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dic 2007

Content Type:

Company Response

Available languages: English
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dic 2007

Content Type:

Company Response

Available languages: English
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dic 2007

Content Type:

Company Response

Available languages: English
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dic 2007

Content Type:

Company Response

Available languages: English
Oxfam report "Investing for Life": Company responses

Data:

12 Dic 2007

Content Type:

Article

Available languages: English
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Data:

27 Nov 2007

Content Type:

Article

Available languages: español
Oxfam says top drug companies focusing on patents, not poor

Data:

26 Nov 2007

Content Type:

Article

Available languages: English
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Data:

23 Nov 2007

Content Type:

Article

Available languages: français
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Nov 2007

Content Type:

Company Response

Available languages: English
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

Data:

1 Nov 2007

Content Type:

Article

Available languages: English

View full story

Load more View less

Business & Human Rights
Resource Centre

Business & Human Rights Resource Centre

This page is not available in Italiano and is being displayed in French

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Sequenza temporale

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Oxfam report "Investing for Life": Company responses

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Oxfam says top drug companies focusing on patents, not poor

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices